Peritoneal Dialysis Alters Tolbutamide Pharmacokinetics in Rats with Experimental Acute Renal Failure

• AIBA Tetsuya

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

• HORIUCHI Mizuki

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

• MAKITA Takashi

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

• KOMORI Yukiko

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

• KAWASAKI Hiromu

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

• KUROSAKI Yuji

  Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

抄録

  The plasma concentration profile of the antidiabetic agent tolbutamide was investigated in glycerol-induced acute renal failure (ARF) rats receiving or not receiving peritoneal dialysis (PD) to assess the impact of performing dialysis on tolbutamide pharmacokinetics. It was revealed that the plasma concentration of tolbutamide was decreased by 23.4% by performing PD in ARF rats, while it was not changed by PD in normal rats. The decrease in the plasma concentration of tolbutamide was nearly proportional to the increase in its volume of distribution. To clarify the mechanisms responsible for the decreased tolbutamide concentration caused by PD, the plasma protein binding of tolbutamide was examined in normal and ARF rats. The plasma unbound fraction of tolbutamide was higher in ARF rats than in normal rats, and the dissociation constants were 3.5±0.7 and 5.5±0.2 μg/mL in normal and ARF rats, respectively. These results indicated that the unbound fraction of tolbutamide was increased in ARF rats because of its protein binding being suppressed. It is therefore likely that since a measurable amount of tolbutamide can distribute in peritoneal dialysate in ARF rats, but not in normal rats, the plasma concentration of tolbutamide was decreased by performing PD only in ARF rats. These findings suggest that diabetes medication with tolbutamide should be carefully performed in patients receiving dialysis treatment.<br>

収録刊行物

• Ｄｒｕｇ　Ｍｅｔａｂｏｌｉｓｍ　ａｎｄ　Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ

  Ｄｒｕｇ　Ｍｅｔａｂｏｌｉｓｍ　ａｎｄ　Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ 21 (4), 291-296, 2006

  日本薬物動態学会

キーワード

• peritoneal dialysis
• tolbutamide
• protein binding
• distribution volume
• acute renal failure

詳細情報

• CRID: 1390282680155511808
• NII論文ID: 10018042852
• NII書誌ID: AA1162652X
• DOI: 10.2133/dmpk.21.291
• COI: 1:CAS:528:DC%2BD28XhtVOmtb7F
• ISSN: 18800920
• ISSN: 13474367
• PubMed: 16946556
• Web Site: http://api.elsevier.com/content/article/PII:S1347436715306996?httpAccept=text/xml
• Web Site: http://api.elsevier.com/content/article/PII:S1347436715306996?httpAccept=text/plain
• Web Site: https://search.jamas.or.jp/link/ui/2007071239
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可